6-Amino-5-fluoropyrimidin-2(1H)-one 5-氟胞嘧啶
CAS 2022-85-7 MFCD00006035
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Antibiotics A to Z, Antibiotics A-F, Antifungal, Chemical Structure Class, Interferes with DNA Synthesis, Interferes with Protein Synthesis, Mechanism of Action, Nucleosides, Spectrum of Activity, Wavelength Index, 发光化合物及其检测, 抗生素, 生化试剂
- {SNA} Analytical Standards, EP Standards, EP Standards E - F, Pharmacopeia Metrological Institutes Standards, 分析/色谱
- {SNA} Analytical Standards, Analytical/Chromatography, Chromatography, EP Standards, EP Standards E - F, Pharmaceutical Standards, Pharmacopeia Standards
- {SNA} Antibiotics,
安全信息
GHS Symbol

- P201 Obtain special instructions before use. 使用前获取专门指示。
- P202 Do not handle until all safety precautions have been read and understood. 已阅读并理解所有的安全预防措施之前,切勿操作。
- P281 Use personal protective equipment as required. 使用所需的个人防护装备。
- P308+P313
- P405 Store locked up. 上锁保管。
- P501 Dispose of contents/container to..… 处理内容物/容器.....
- H341 Suspected of causing genetic defects 怀疑导致遗传性缺陷
- H361 Suspected of damaging fertility or the unborn child 怀疑对生育能力或未出生婴儿造成伤害
- S36/37 Wear suitable protective clothing and gloves 穿戴适当的防护服和手套;
- S45 In case of accident or if you feel unwell seek medical advice immediately (show the label where possible) 发生事故时或感觉不适时,立即求医(可能时出示标签);
- R36/37/38 Irritating to eyes, respiratory system and skin 对眼睛、呼吸系统和皮肤有刺激性
- R40 Limited evidence of a carcinogenic effect 有限证据表明其致癌作用
- R63 Possible risk of harm to the unborn child 可能危害未出生婴儿
- R68 Possible risk of irreversible effects 可能有不可挽回的作用的危险
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >15 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,699,1982
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 3336 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 21,935,1979
TYPE OF TEST : LD50 - Let
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 1080 mg/kg/10D-I TOXIC EFFECTS : Brain and Coverings - other degenerative changes Behavioral - changes in motor activity (specific assay) Behavioral - ataxia REFERENCE : EJCPAS European Journal of Clinical Pharmacology. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.3- 1970- Volume(issue)/page/year: 51,,505,1997
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 3811 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,710,1979
TYPE OF TEST : Mutation test systems - not otherwise specified TEST SYSTEM : Microorganism - not otherwise specified DOSE/DURATION : 100 mg/L REFERENCE : JMMIAV Journal of Medical Microbiology. (Longman Group UK Ltd., Longman House, Burnt Mill, Harlow, Essex CM20 2JE, UK) V.1- 1968- Volume(issue)/page/year: 12,83,1979
TYPE OF TEST : Mutation in microorganisms TEST SYSTEM : Yeast - Saccharomyces cerevisiae DOSE/DURATION : 8 mg/L REFERENCE : MGGEAE Molecular and General Genetics. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.99- 1967- Volume(issue)/page/year: 146,253,1976
TYPE OF TEST : DNA inhibition TEST SYSTEM : Microorganism - not otherwise specified DOSE/DURATION : 100 mg/L REFERENCE : JMMIAV Journal of Medical Microbiology. (Longman Group UK Ltd., Longman House, Burnt Mill, Harlow, Essex CM20 2JE, UK) V.1- 1968- Volume(issue)/page/year: 12,83,1979
其他信息
- 方法一:由5-氟尿嘧啶经氯化、氨化、水解而得。1.氯化将5-氟尿嘧啶和三氯氧磷加入氯化锅,搅拌,控制在20℃以下滴加N,N-二甲基苯胺。滴加完毕,升温到110℃左右反应2h。冷至室温,放至冰盐水中冰解,维持15℃搅拌1h。过滤,水洗,得2,4-二氯-5-氟嘧啶。2.氨化将2,4-二氯-5-氟嘧啶溶解在乙醇中,搅拌,控制在35℃以下滴加氨水。滴毕,降温至25℃反应3h,减压回收乙醇至干,加水搅拌升温到20℃。过滤,用水洗涤结晶,干燥,得出4-氨基-2-氯-5-氟嘧啶。3.水解将4-氨基-2-氯-5-氟嘧啶和盐酸混合,搅拌升温至90-95℃,反应2h后,减压浓缩至干,加水溶解结晶,加活性炭脱色。过滤,滤液用氨水调pH至7-8,放置过夜。甩滤,用水洗涤结晶,经精制即得氟胞密啶。总收率50%。该法的起始原料为抗癌药氟尿嘧啶[51-21-8],也可以采用氟尿嘧啶的前体,即2-甲氧基-4-羟基-5-氟嘧啶为原料,经氯化,氨化,水解制备氟胞嘧啶,收率70%。将上述前体加入甲苯中,再加入二甲基苯胺,加热至50-60℃,滴加三氯氧磷。然后105-110℃反应3h。冷却至室温,将反应液加入甲苯和水的混合液中,在25-40℃搅拌。分出甲苯层,水层用甲苯提出取,将提出取液与甲苯层合并,先减压回收甲苯,再收集86-90℃(2.66kPa)馏分
- Sigma Aldrich:2022-85-7(sigmaaldrich)
- 用途三:该品在国外作为治疗严重全身性白色含珠菌及隐球菌感染的首选药物[收入《美国药典》(第19版)],用于真菌性髓膜炎,真菌性呼吸道感染及黑色真菌症的治疗。
- Acros Organics:5-氟胞嘧啶 5-Fluorocytosine, 98%(2022-85-7)
- MOL 文件:2022-85-7.mol
- 5-氟胞嘧啶价格(试剂级):更新日期 产品编号 产品名称 包装 价格 2011/08/23 K4685001 5-氟胞嘧啶 250mg 228元 2011/04/16 F0321 5-氟胞嘧啶 5-Fluorocytosine 1G 469元 2011/04/16 F0321 5-氟胞嘧啶 5-Fluorocytosine 25G 3960元
- MSDS 信息:2-Hydroxy-4-amino-5-fluoropyrimidine(2022-85-7).msds
- 用途一:用于治疗隐球菌和念珠菌等所致的真菌感染,如真菌败血症、心内膜炎、脑膜炎及肺部和泌尿道感染
- 图谱信息:5-氟胞嘧啶(2022-85-7)红外图谱(IR1) 5-氟胞嘧
- 方法一:由5-氟尿嘧啶经氯化、氨化、水解而得。1.氯化将5-氟尿嘧啶和三氯氧磷加入氯化锅,搅拌,控制在20℃以下滴加N,N-二甲基苯胺。滴加完毕,升温到110℃左右反应2h。冷至室温,放至冰盐水中冰解,维持15℃搅拌1h。过滤,水洗,得2,4-二氯-5-氟嘧啶。2.氨化将2,4-二氯-5-氟嘧啶溶解在乙醇中,搅拌,控制在35℃以下滴加氨水。滴毕,降温至25℃反应3h,减压回收乙醇至干,加水搅拌升温到20℃。过滤,用水洗涤结晶,干燥,得出4-氨基-2-氯-5-氟嘧啶。3.水解将4-氨基-2-氯-5-氟嘧啶和盐酸混合,搅拌升温至90-95℃,反应2h后,减压浓缩至干,加水溶解结晶,加活性炭脱色。过滤,滤液用氨水调pH至7-8,放置过夜。甩滤,用水洗涤结晶,经精制
- F:10-23
- TCI Shanghai:5-氟胞嘧啶 5-Fluorocytosine,>;98.0%(LC)(T)(2022-85-7)
- Alfa Aesar:5-氟胞苷,98+% 5-Fluorocytosine, 98+%(2022-85-7)
- 上游原料:三氯氧磷 --> N-甲基苯胺 --> 5-氟脲嘧啶 --> 4-氨基-2-氯-5-氟嘧啶 --> 2,4-二氯-5-氟嘧啶 --> 2-甲氧基-4-羟基-5-氟嘧啶
- 敏感性:Light Sensitive
- 用途二:抗真菌药。主要用于皮肤黏膜念珠菌病、念珠菌心内膜炎、念珠菌关节炎、隐球菌脑膜炎和着色真菌病。用药期间应定期检查血象。肝、肾功能不全血液病患者及孕妇慎用;严重肾功能不全患者禁用。